August 1, 2022 Clinical Research/Diagn. Environ, Ag./Food & Bev Lab Top-10 PAI Top-10

PerkinElmer Accelerates Transformation into High Growth, High Margin Life Sciences & Diagnostics Company

Enters agreement with intention to divest Applied, Food and Enterprise Services businesses WALTHAM, Mass.–(BUSINESS WIRE)–Aug. 1, 2022– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced it has entered into an agreement with the intention to divest its Applied, Food and Enterprise Services businesses to New Mountain Capital,... Read more

July 27, 2022 Clinical Research/Diagn. Environ, Ag./Food & Bev Lab Top-10

Two PerkinElmer Tests Added to UK’s Updated NICE Diagnostic Guidance for Suspected Preterm Pre-Eclampsia

WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that a placental growth factor (PlGF) measurement using its DELFIA® Xpress PlGF 1-2-3TM kit (CE-IVD) and a soluble fms-like tyrosine kinase 1 (sFlt-1)/PlGF ratio using its DELFIA® Xpress sFlt-1 kit (CE-IVD), have been included in an updated diagnostic guidance issued by the United Kingdom’s National... Read more

July 11, 2022 Atomic Spectroscopy Clinical Research/Diagn. Lab Top-10 Microscopy Molecular Spectroscopy Product Launch

Bruker Announces Three New GHz NMR Systems Orders for Functional Structural Biology and Clinical Phenomics Research

Three Labs in Japan and Spain to Receive Novel Compact Ascend Evo 1.0 GHz Magnets UTRECHT, The Netherlands–(BUSINESS WIRE)– At the Euromar 2022 Conference, Bruker announced three new customer orders for GHz systems, which will incorporate novel, compact 1.0 GHzNMR magnets for structural biology applications and clinical research in single-story laboratories. The new Ascend Evo... Read more

July 6, 2022 Atomic Spectroscopy Clinical Research/Diagn. Lab Top-10 Liq. Handling & Robotics Molecular Spectroscopy Product Launch

Bruker Launches NMR-based Molecular Phenomics Clinical Research Tool for ‘Long COVID’ Multi-Organ Risk Assessment

ETTLINGEN, Germany–(BUSINESS WIRE)– Bruker Corporation (Nasdaq: BRKR) today has launched PhenoRiskPACS™ RuO, a research-use-only NMR test for molecular phenomics research on ‘Long COVID’ patients’ blood samples, using a multiplexed combination of biomarkers discovered at the Australian National Phenome Center (ANPC) at Murdoch University, under Director Jeremy Nicholson. The PhenoRiskPACS™ RuO test is promising for research... Read more